ALS Biopharma, LLC
Mar. 24, 2011: ALS Biopharma is pleased to announce that the company has been granted orphan drug designation by the U.S. Food and Drug Administration for heat shock protein Hsp70 for the treatment of amyotrophic lateral sclerosis.
The Office of Orphan Products Development of theU.S. Food and Drug Administration has granted the application of ALS Biopharma for orphan drug designation for heat shock protein Hsp70 for the treatment of amyotrophic lateral sclerosis, as reported in a letter received from the FDA dated Mar. 18, 2011. This designation is significant because it is possible that Hsp70, or Hsp70-based therapy, may prove to be effective for the treatment of ALS in patients based upon the research of collaborator Prof. Carolanne Milligan of Wake Forest University.
